MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive
therapy with use of MSCs and CY in patients at high risk of relapse.